PeptiSystems signs distribution agreement with Gene Company Limited for Greater China region
PeptiSystems AB, a leading innovator in flowthrough peptide and oligonucleotide synthesis technology, is pleased to announce a new distribution agreement with Gene Company Limited, a well-established life sciences and biotechnology distributor in China. Through this partnership, Gene will become the distributor of PeptiSystems’ new-generation peptide and oligonucleotide synthesizers in China, Hong Kong, and Macau.
This strategic partnership is a significant step for PeptiSystems as it expands its footprint in the rapidly growing pharma, biotech, and CDMO markets in Greater China. By partnering with Gene, PeptiSystems will leverage Gene extensive regional network and market expertise to deliver innovative peptide and oligonucleotide synthesis technology to industry professionals across this dynamic region.
“We are excited to join forces with Gene, a respected distributor with a strong presence from 30 years of doing business in the Greater China region,” said Karin Granath, CEO of PeptiSystems. “Our agreement with Gene will ensure that more customers have access to our best-in-class peptide and oligonucleotide synthesizers, furthering our mission to support PeptiSystems’ transformational flow through technology and strategic expansion in this fast-growing market.”
“It is our pleasure to work with PeptiSystems, which is one of the important pioneer and expert in the field of Oligonucleotide and Peptide synthesis”, said Idy Leung, Business Support Manager of Gene Company. “We wish our collaboration will provide great opportunities and development on Oligonucleotide and Peptide manufacturing, especially in pharmaceutical and related fields in the Greater China region”.
For more information, please contact:
Karin Granath, CEO
Phone: +46 702-82 07 47
Email: karin.granath@peptisystems.com
About PeptiSystems AB
PeptiSystems is a biotech company developing a new generation of flow-through instruments for peptide and oligonucleotide therapeutics synthesis. Utilizing proprietary flow-through column technology, PeptiSystems' instruments significantly reduce production times, enhance synthesis control, and minimize raw material consumption while maintaining high purity and yield. With scalability in mind, these next-generation synthesis instruments seamlessly adapt from small-scale development to large-scale production, enabling pharmaceutical companies and CDMOs to meet the growing global demand for high-performance, cost-effective, and sustainable manufacturing processes. PeptiSystems is headquartered in Uppsala, Sweden. For more information, please visit www.peptisystems.com and follow us on LinkedIn.